India, July 13 -- image credit- getty images

Emcure Pharmaceuticals has announced the consolidation of its shareholding in biopharma subsidiary Gennova Biopharmaceuticals, alongside a leadership transition, as it sharpens its focus as a biologics and biosimilars company.

Emcure is acquiring the entire 12.05% minority stake in Gennova held by Dr Sanjay Singh and others, taking its ownership to 100% and making Gennova a wholly owned subsidiary. Gennova will be led by Samit Mehta and will focus on its biologics franchise - Elaxim(R)/TENECTASE(R), Vintor(R), Xgrast(R)/PEGEX(R) and Hamsyl(R) - biosimilars development, and adjacent therapeutic platforms, leveraging its established mammalian and microbial biomanufacturing platforms.

Samit Meh...